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CCR-5 is a major cellular coreceptor for R5 strains of HIV-1. Individuals carrying a homozygous 32-base-pair deletion in
this gene are apparently healthy and are relatively resistant to HIV-1 infection. Since CCR5 appears to be dispensable for the
host, but important for initial HIV-1 infection, CCR5 mRNA is an excellent therapeutic target for inhibiting HIV-1 replication via
ribozyme knockout. We report here that hairpin ribozymes are able to reduce cellular CCR5 mRNA and cell surface CCR5
when stably introduced into PM1 cells by transduction with recombinant adenoassociated viral vector. The ribozymes
effectively protect the cells from infection by R5 HIV-1 strains or non-syncytium-inducing clinical isolates commensurate with
a reduction in CCR5 mRNA. These results suggest a novel gene therapy approach to preventing or slowing the disease
progression of HIV-1 infection. © 2000 Academic Press
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aEntry of HIV type 1 (HIV-1) into human CD41 cells
equires certain chemokine receptors expressed on the
arget cell surface such as the coreceptor for HIV-1
nvelope glycoproteins (env) (for reviews see Berger,
997; Doranz et al., 1997; Moor et al., 1997). The core-
eptor interacts with the V3 loop of gp120 of env which
ecomes exposed following the initial binding of env to
D4 on the target cell surface (Wu et al., 1996).
CCR5 and CXCR4 are two major coreceptors used by
acrophage tropic (M-tropic or R5) and T cell line tropic
T-tropic or X4) HIV-1 strains, respectively (for review see
erger, 1997; Doranz et al., 1997; Moor et al., 1997). Both
f them can also be used by duotropic strains. In addition
o CCR5 and CXCR4, other closely related chemokine
eceptors such as CCR1, CCR2b, CCR3, STRL33/Bonzo,
nd BOB may also serve as coreceptors for some HIV-1
trains (Deng et al., 1997; Liao et al., 1997). Among these
oreceptors, CCR5 is often used by HIV-1 to establish
nitial infection. The majority of individuals who lack a
unctional CCR5 due to a homozygous 32-base-pair de-
etion in the CCR5 gene appear relatively resistant to HIV
nfection (Liu et al., 1996; Paxton et al., 1996; Samson et
l., 1996a). Individuals who are heterozygous for the
CR5 delta 32 mutation have a lower level of CCR5
xpression than the homozygotes carrying the wild-type
CR5 gene (Wu et al., 1997). Although there is no indi-
ation that the heterozygotes are less susceptible to
IV-1, some evidence shows that the disease progres-a
1 To whom correspondence and reprint requests should be ad-
ressed. Fax: (858) 824-1112. E-mail: barber@immusol.com.
271ion in HIV-1-infected heterozygotes is often slower than
hat of the infected individuals homozygous for the wild-
ype CCR5 gene (Buseyne et al., 1998; Eugen-Olsen et
l., 1997; Paxton et al., 1998a,b). Taken together, these
bservations suggest that elimination or even partial
eduction of CCR5 may protect individuals from HIV-1
nfection or slow down disease progression. Since CCR5
s dispensable for normal cellular and physiological func-
ion (Liu et al., 1996; Paxton, 1996; Samson et al., 1996a),
t could be an attractive target for ribozyme-mediated
ene therapy.
Recently, several different approaches have been
sed to inhibit the cellular expression of CCR5 and
XCR4 (Bai et al., 1998; Carroll et al., 1997; Chen et al.,
997; Yang et al., 1998). One of them employs anti-CCR5
ibozymes. It was reported that the addition of synthetic
ammerhead ribozymes was able to inhibit CCR5 ex-
ression when both CCR5 and the ribozymes were tran-
iently transfected into HeLa or HEK 293 cells (Goila and
anerjea, 1998; Gonzalez et al., 1998). Transient trans-
ection of synthetic ribozymes, however, is unlikely to be
f therapeutic benefit, since RNA is highly unstable in
ells. Furthermore, these studies did not determine
hether anti-CCR5 ribozymes were able to reduce en-
ogenous CCR5 and, if so, whether such a reduction in
CR5 could render the cells resistant to HIV-1 infection.
hese two questions are important to determine whether
nti-coreceptor ribozymes can be used in gene therapies
gainst HIV-1 infection.In this report, we describe a ribozyme gene therapy
pproach to HIV treatment. Intracellular delivery and
0042-6822/00 $35.00
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272 FENG ET AL.expression of catalytically active hairpin ribozyme genes,
directed against CCR5, are achieved using recombinant
adenoassociated virus (rAAV) vectors. Constitutive intra-
cellular production of these ribozymes resulted in a re-
duction of endogenous CCR5 mRNA and protein in the
vector-transduced cells. More importantly, introduction of
these ribozyme genes substantially reduced the suscep-
tibility of the cells to infection by R5 HIV-1 but not X4
HIV-1 strains. Therefore, these anti-CCR5 ribozyme
genes may be utilized as an effective gene therapy,
perhaps in combination with ribozyme genes that target
the viral RNA directly (for reviews see Welch et al., 1996a;
u et al., 1994) or in combination with current antiviral
rugs therapies, as an optimal treatment for HIV infec-
ion.
RESULTS
n vitro kinetic characterization of anti-CCR5 hairpin
ibozymes
Based on the human CCR5 mRNA sequence, 53-nu-
leotide-long hairpin ribozymes which contain 4 base
nd 8 base-target recognition sequences were synthe-
ized according to the previously characterized hairpin
ibozyme motif (Hampel, 1998). Initially, eight distinct
andidate ribozymes were screened for cleavage activity
n vitro against their respective 19-nucleotide CCR5 RNA
ubstrates. Preliminary experiments with these ri-
ozymes indicated that five of eight showed substantial
leavage of their respective target RNAs in vitro (data not
hown). These five ribozymes, designated R5-14, R5-150,
5-392, R5-670, and R5-897 (the number indicates the
leavage sites in CCR5 mRNA relative to the AUG protein
ranslation start site (Combadiere et al., 1995; Samson et
l., 1996b), were further characterized for their kinetic
roperties. The catalytic properties of these ribozymes
aried widely (Table 1), but are comparable to that of the
reviously tested anti-HIV, HBV, and HCV ribozymes,
TABLE 1
Kinetic Parameters of Anti-CCR5 Ribozymes
Ribozyme
Km
(nM) kcat
kcat/Km
(104 M21 min21)
R5-14 8.9 0.065/min 730
R5-150 15 0.16/min 1067
R5-392 9.7 0.15/min 1598
R5-670 17 0.12/min 676
R5-897 65 0.12/min 184
Native ribozyme 17 0.63/min 3705
Note. The ribozyme concentration was 4 nM and the substrate
concentration ranged from 4 to 250 nM.hich have sufficient potency to produce antiviral activity
Welch et al., 1996a,b, 1997).
p
tn vivo expression of CCR5 ribozyme genes
Three of the five catalytically characterized ribozymes
ere selected for further analysis by ribozyme gene
herapy in vivo. The choice of ribozyme was based on (1)
heir ability to cleave their respective target RNAs in vitro
Table 1) and (2) their specificity for CCR5, as determined
y the uniqueness of their target recognition domains (at
east three base pair differences compared with all
nown human sequences). For in vivo expression of the
hairpin ribozymes, double-stranded oligonucleotides en-
coding ribozymes R5-14, R5-392, and R5-897, respec-
tively, were cloned into an adenoassociated virus (AAV)-
based vector plasmid, pAMFT, directly downstream of a
tRNA valine promoter (Fig. 1), such that the ribozyme
synthesized by RNA polymerase III would be processed
as cellular tRNA. The plasmids were then used to gen-
erate rAAV vector particles capable of delivering each
individual ribozyme gene and the neo-aminoglycoside
phosphotransferase gene.
The human T cell line, PM1, was then transduced with
the rAAV vectors and selected in G418-containing me-
dium. This cell line expresses both CXCR4 and CCR5
and is therefore susceptible to infection by both CXCR4-
specific and CCR5-specific HIV-1 strains (Lusso et al.,
1995). The use of this cell line facilitated the test of the
specificity of the ribozymes, since ribozymes directed
specifically against CCR5 should inhibit R5 HIV-1 strains,
but not X4 HIV-1 strains that require CXCR4 for viral entry.
As controls, PM1 cells were also transduced with rAAV
vectors encoding the corresponding “disabled” ri-
bozymes, whose catalytic activity had been inactivated
through mutation of three bases known to be required for
ribozyme cleavage activity (Welch et al., 1997). After sta-
bly transduced PM1 cells were selected, the chromo-
some-integrated inserts were verified by PCR and DNA
sequencing. The expression of ribozymes was also con-
firmed by reverse transcriptase (RT) PCR (data not
shown).
FIG. 1. Structure of the rAAV ribozyme expression plasmid pAMFT.
pAMFT is constructed on the basis of the retroviral vector plasmid
pLNL6. The diagram shows only the section between the AAV
inverted terminal repeats (ITR). The selection marker neo-aminogly-
coside phosphotransferase (neor) coding region is linked to an
pstream long terminal repeat (LTR) promoter derived from the
oloney murine leukemia virus genome. DNA encoding CCR5 ri-
ozymes is placed downstream of a tRNA valine promoter. pA, SV40
olyadenylation site; term, pol III termination site. The arrow shows
he direction of transcription.
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273HIV-1 REPLICATION INHIBITION BY HAIRPIN RIBOZYME GENE THERAPYIn vivo cleavage of CCR5 mRNA by CCR5 ribozymes
esults in a decrease in CCR5 expression
To determine whether in vivo expressed CCR5 ri-
ozymes were able to cleave CCR5 mRNA, total mRNA
as extracted from the parental PM1 cells and the cells
ransduced to express CCR5 ribozymes. The level of
CR5 mRNA expression was determined using Northern
lot analysis with 32P-labeled CCR5 cDNA fragments as
the hybridization probe. The CCR5 mRNA was then nor-
malized to the cellular b-actin mRNA level, which was
used as an internal standard. As shown in Fig. 2, the
mRNA level in the cells expressing R5-14 was reduced
by 77% of that in the parental PM1 cells. In the cells
expressing R5-392 and R5-897, CCR5 mRNA decreased
at least 50%, whereas in the cells expressing disabled
ribozymes, there was no decrease in CCR5 mRNA ex-
pression. The differences in mRNA level observed for
different ribozymes do not seem to correlate with enzy-
matic activity. This may reflect variable steric availability
of the specific target sites by each ribozyme, due to RNA
folding or, more likely, RNA binding proteins in vivo.
Next, the cell surface CCR5 was measured to deter-
mine whether the ribozyme-mediated reduction in CCR5
mRNA would yield meaningful changes in CCR5 surface
expression. The PE-conjugated anti-CCR5 monoclonal
antibody 2D7/CCR5 from PharMingen was used to label
the CCR5 on R5-14 cells. Surface expression is detect-
able on 18% of PMI cells, which is in agreement with
previously published results of 20% positive staining for
PM1 cells (Wu et al., 1997). In the case of the R5-14-
expressing cells, about 80% reduction in the surface
CCR5 protein was consistently observed (Fig. 3). Thus
FIG. 2. Northern blot analysis of the cellular CCR5 mRNA. A Northern
lot of mRNA isolated from parental PM1 cells and the cells transduced
o express CCR5 ribozymes or their disabled counterparts (D) was
ybridized with CCR5-specific probes and then with b-actin-specific
probes for normalization of RNA loaded. The relative CCR5/b-actin is
expressed as the relative ratio of the phosphorimage density of CCR5
mRNA to b-actin mRNA while the ratio of the parental PM1 cell mRNAs
s defined as 100.the reduction in the cell surface CCR5 correlates with the
decrease in the cellular CCR5 mRNA.Inhibition of CCR5-dependent cell fusion by in vivo
expression of CCR5 ribozymes
Chemokine receptors facilitate entry of HIV-1 into cells
by allowing fusion of the HIV env-containing viral parti-
cles to the target cell membrane containing CD4 and the
chemokine receptor. To test the effect of CCR5 ribozymes
on the coreceptor-dependent fusion event, an experi-
mental cell/cell fusion assay was used that mimics many
of the characteristics of virus/cell fusion. Fusion between
the cells expressing HIV-1 env and the target cells ex-
pressing CD4 and the coreceptors requires a specific
match between the type of HIV-1 env and the corecep-
tors (for reviews see Berger, 1997; Doranz et al., 1997;
oor et al., 1997). Thus the cell fusion assay can be
mployed to determine the functional protein level of
CR5 on the cell surface.
To make HIV-1 env and T7 RNA polymerase-express-
ng cells, HeLa cells were coinfected with two vaccinia
ecombinants, vTF7-3 and either vCB43 or vSC60. vTF7-3
ontains a bacteriophage RNA polymerase expression
assette under the control of a vaccinia early/later pro-
oter. vCB43 contains an expression cassette of R5
IV-1 Ba-L env. vSC60 contains a expression cassette of
4 HIV-1 IIIB env. The resulting HeLa cells express high
evels of HIV-1 env on the cell surface and T7 RNA
olymerase in the cytoplasm. The fusion partner PM1
ells were infected with vaccinia recombinant vCB21R-
FIG. 3. FACS analysis of the cell surface CCR5. The cells were
incubated with PE-conjugated mouse anti-CCR5 monoclonal antibody
2D7/CCR5 and then analyzed on a FACScan flow cytometer, using an
isotype control to set the gating. (A) The PM1 cells expressing the
ribozyme R5-14. (B) Parental PM1 cells.
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274 FENG ET AL.lacZ and vCB3. vCB21R-lacZ contains a lacZ gene under
the control of a T7 promoter. vCB3 contains a expression
cassette of CD4 under the control of a vaccinia early/
later promoter. The resulting PM1 cells overexpress CD4
molecules on the cell surface. Overexpression is neces-
sary to stimulate the otherwise inefficient process of cell
fusion. After these two populations of vaccinia recombi-
nant-infected cells are mixed together, if cell fusion oc-
curs, T7 RNA polymerase in HeLa cells will transcribe
the lacZ gene in the PM1 cells to produce b-galactosi-
dase. The degree of cell fusion thus can be quantified
according to the relative activity of b-galactosidase.
Since both CD4 and HIV-1 env are overexpressed in
his cell fusion system, the only limiting factor for cell
usion would be expected to be the coreceptor. The
b-galactosidase activity should correlate with the level of
the coreceptor on the cell surface. In order to compare
the CCR5-dependent cell fusion between different sam-
ples, the CCR5-dependent fusion data in Fig. 4 are nor-
malized to the level of the CXCR4-dependent cell fusion.
For all samples we tested, expression of hairpin ri-
bozymes did not show any inhibitory effect on the
CXCR4-dependent cell fusion (data not shown). As
shown in Fig. 4, the fusion between the PM1 cells ex-
pressing R5-14 and HeLa cells expressing Ba-L env is
about 50% of that between the parental PM1 cell and the
HeLa cells. A decrease in cell fusion was also observed
for the PM1 cells expressing R5-392 and R5-897, but the
reduction is only about 30%. PM1 cells expressing dis-
abled ribozymes R5-14D, R5-392D, and R5-897D had no
FIG. 4. HIV-1 env-mediated cell fusion. HeLa cells infected with
accinia recombinants to express T7 RNA polymerase together with
ither Ba-L or IIIB env were mixed with the transduced or parental PM1
ells overexpressing CD4. Cell fusion was analyzed based on the
elative b-galactosidase activity. The transduced PM1 cells were ex-
pressing each of the active ribozymes R5-14, R5-392, and R5-897 and
the disabled counterparts (D). Error bars show the standard deviation
of two measurements.significant change in cell fusion. These data indicate that
the ribozyme-mediated decrease in surface CCR-5 issufficient to inhibit HIV-1 env/CD4-dependent membrane
fusion. Since this cell/cell fusion model assay only par-
tially resembles the more facile virus/cell fusion process,
the data should not be taken as a quantitative prediction
of anti-viral effects.
Inhibition of CCR5-dependent HIV-1 infection by
intracellular expression of CCR5 ribozyme
To determine whether intracellular CCR5 ribozymes
were able to specifically protect PM1 cells from R5 HIV-1
infection, the transduced cells were challenged with R5
HIV-1 strain Ba-L at an m.o.i. of 0.02. The progress of the
resultant infection was followed by measuring p24 cap-
sid protein in the medium. The data in Fig. 5 indicate that
all three ribozymes, R5-14, R5-392, and R5-897, were
capable of substantially inhibiting HIV replication
throughout the 15-day experiment. To test the specificity
of the anti-viral effect, ribozyme gene-transduced PM1
cells were infected with either X4 HIV-1 strain IIIB or an
R5 HIV strain Ba-L. The virion production was measured
on day 15 postinfection. The cells transduced with ri-
bozyme genes R5-14, R5-392, and R5-897 were all highly
resistant to Ba-L infection (Fig. 5A). Virion production
during 15 days postinfection was inhibited by greater
than 99% for all three ribozymes, which is comparable to
the inhibition with 100 nM RANTES, a natural ligand of
CCR5 (Fig. 5A). The inhibition of viral replication by anti-
CCR5 ribozymes was highly specific, since the same
cells that were protected from R5 HIV stain Bal-1 infec-
tion retained susceptibility to X4 HIV strain IIIB, which
uses CXCR4 as the coreceptor instead of CCR5 (Figs. 5A
and 5B). Furthermore, the data in Fig. 5 indicate that
ribozyme enzymatic cleavage activity was absolutely re-
quired for the observed inhibition of Bal-1 HIV replica-
tion, since cells transduced with catalytically “disabled”
ribozymes were fully susceptible to infection by both
Ba-L and IIIB. Thus, an antisense effect on the ribozyme
target recognition domain alone cannot account for the
observed results, as the disabled ribozymes lack enzy-
matic activity, but maintain the complementary target
recognition domain.
In order to determine whether anti-CCR5 ribozymes
can protect cells against uncloned HIV-1 primary iso-
lates (quasispecies), a non-syncytium-inducing clini-
cal isolate (076-0326) from an infected patient was
used to challenge the PM1 cells expressing R5-14. The
R5-14 transduced cells were chosen because it
showed greatest apparent reduction in levels of mRNA
for CCR5 by Northern blotting (Fig. 2). As shown in Fig.
5C, R5-14 showed significant antiviral activity (.90%
reduction of p24) against the clinical isolate compared
with the disabled R5-14, indicating that CCR5 ri-
bozymes are effective at inhibiting replication of HIV
quasispecies.
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In this study, we demonstrated that intracellular ex-
ression of CCR5 ribozymes is able to specifically re-
uce the cellular CCR5 mRNA level, leading to a de-
FIG. 5. (A). Time course for HIV Bal-1 replication. The PM1 cells tran
with the HIV-1 Ba-L at an m.o.i. of 0.02 for 2 h. Viral production was deter
PM1 cells were used as a negative control. Error bars show the st
ribozyme-expressing PM1 cells. Target cells were incubated with the v
(D) are represented by white bars, and cells transduced with each activ
by a p24 antigen assay on day 15 postinfection. (Left) R5 HIV-1 Ba-L was
during infection and postinfection. (Right) X4 HIV-1 IIIB was used. In
Challenge of PM1 and the R5-14-expressing PM1 cells by HIV-1 quasi
quasispieces (076-0326) isolated from a infected patient at an m.o.i. o
function of time postinfection.rease in cell surface CCR5. As a result of reduction of
CR5 on the cell surface, CD4/HIV env-mediated mem-
r
prane fusion is inhibited and the cells become resistant
o R5 HIV-1 but not X4 HIV-1 infection. Such a high
pecificity makes CCR5 ribozymes suitable for use in
ene therapies against HIV-1 infection. Moreover, hairpin
to express CCR5-ribozyme R5-14, R5-392, and R5-897 were incubated
by a p24 antigen assay as a function of time postinfection. The parental
deviation of triplicate measurements. (B). HIV-1 challenge of CCR5
an m.o.i. of 0.02 for 2 h. Cells transduced with each disabled ribozyme
yme are represented by shaded bars. Viral production was determined
RANTES (100 nM) was used as a control (black bar) which was present
ase, untransduced PM1 cells were used as a negative control. (C).
s. The target cells were incubated with non-syncytium-inducing HIV-1
or 2 h. Viral production was determined by a p24 antigen assay as asduced
mined
andard
irus at
e riboz
used.
each c
specieibozyme is a small RNA molecule. When stably ex-
ressed in cells, CCR5 ribozyme does not have any
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276 FENG ET AL.deleterious effects. If gene transfer technologies allow
CCR5 ribozyme to be expressed in a sufficiently large
population of CD41-T lymphocytes in humans, these
cells will become resistant to R5 HIV-1 and thus be able
activate cytotoxic T lymphocytes and B lymphocytes
upon HIV infection. The resulting antiviral immune re-
sponses could slow down the disease progression.
According to our results, the susceptibility of the cells
expressing CCR5 ribozyme to R5 HIV-1 may not linearly
correlate with the amount of residual CCR5 expression.
Based on expression data (i.e., Northern blot and cell
fusion assays), compared with our standard HIV chal-
lenge experiments, the differences in CCR5 among cell
lines were not reflected in the degree of infectability. We
hypothesize that there may be a threshold of CCR5 and
CD4 on the target cell surface which is necessary for
efficient entry of HIV-1, as has been previously shown for
CXCR4 and CD4 (Dimitrov et al., 1999; Xiao et al., 1999).
Indeed, there is some evidence showing that CD4 con-
stitutively interacts with CCR5 on the cell surface of
primary CD41T cells and macrophages that are known to
e susceptible to the R5 HIV-1 and that CCR5 that does
ot associate with CD4 cannot be efficiently used by HIV
Divitrov et al., 1999; Xiao et al., 1999). This could explain
hy we see effective inhibition of HIV-1 infection, under
ur standard antiviral assay conditions, for all three of
he CCR5 ribozymes despite the observed differences in
he other measurements of their relative activities. If a
hreshold effect exists in vivo, it would imply that com-
lete knockdown of the coreceptor may not be required
or efficient inhibition of HIV infection of ribozyme trans-
uced CD41 cells.
A reduction of cellular CCR5 expression associated
nti-viral effect can also be inferred from HIV-1-infected
ndividuals heterozygous for the CCR5 deletion. These
ndividuals have decreased CCR5 on their lymphocytes
nd have slower disease progression compared with
omozygotes carrying wild-type CCR5 (Buseyne et al.,
998; Eugen-Olsen et al., 1997; Paxton et al., 1998a,b). In
addition, the level of CCR5 expression has been shown
to correlate with infectability of PBMCs by macrophage
tropic HIV-1 in vitro (Wu et al., 1997). Thus this further
suggests that CCR5 ribozymes have the potential to be
used as antiviral drugs against HIV-1.
A recognized concern with blocking the entry of R5
HIV-1 is the potential of providing selective pressure on
HIV-1 to use the other major coreceptor, CXCR4, which is
associated with strains of HIV-1 present during the oc-
currence of AIDS (Este et al., 1999). In order to address
this concern, we are currently developing anti-CXCR4
ribozymes under the control of T-cell-specific promoters,
which can be delivered together with the anti-CCR5 ri-
bozymes into human T cells or hematopoietic stem/
progenitor cells before they differentiate into multilin-
eage progeny cells in vivo. It is also important to note
that it was recently shown by Chen and colleagues (Bai
2et al., 1998; Chen et al., 1997) that the CXCR4 could be
nocked out by an intrakine gene therapy strategy in
rimary lymphocytes with the cells retaining normal bi-
logical functions. The present data suggest that a com-
ination of anti-coreceptor ribozymes and anti-HIV ri-
ozymes may offer one of the most promising ap-
roaches for gene therapy against HIV infection. One
otential problem underlying the recent clinical success
ith antiviral drug regimes against HIV is the generation
f resistant mutants, which may ultimately render triple
rug therapy ineffective. The present anti-CCR5 ribozyme
ene therapy strategy is aimed at the conserved regions
f a cellular gene, which does not have the mutagenic
otential of the HIV viral genome. Furthermore, the anti-
CR5 ribozyme approach is aimed at the entry level of
IV prior to the start of the replication cycle, which
hould limit the possibility of HIV drug-resistant muta-
ions arising.
MATERIALS AND METHODS
iruses and cells
HIV stocks of the IIIB strain were produced in H9 cell
ATCC HTB-176) cultures and the Bal-1 strain was pro-
uced in primary macrophage cultures. Clinical isolates
ere kindly provided by Dr. Stephen A. Spector of the
niversity of California, San Diego, and propagated in
BMCs. Viral stocks were titered on PM1 cells. Vaccinia
ecombinants and PM1 cells were obtained from the NIH
IDS Research and Reference Reagent Program.
ibozyme sequences
The following ribozyme sequences were used:
R14 59 uuggacuuagaacuugaccagagaaacacacggacu-
ucgguccgugguauauuaccuggua;
R392 59 acagcaugagaaacagaccagagaaacacacggacu-
ucgguccgugguauauuaccuggua;
R897 59 uucuccccagaaaaggaccagagaaacacacggacu-
ucgguccgugguauauuaccuggua.
isabled ribozymes (Ojwang et al., 1992) are altered at
ositions 24–26 by changing the AAA in the catalytic
ore to CGU.
n vitro cleavage reactions
The CCR5 ribozymes were generated by in vitro tran-
cription of the synthesized DNA templates of ribozymes
ith T7 RNA polymerase (Welch et al., 1997). The 19-nucle-
tide substrates were synthesized and labeled with
a-32P]UTP. For the in vitro cleavage reaction, the concen-
rations of ribozymes and substrates were 0.0052 and 0.072
mM, respectively. The reactions were assembled on ice in
a buffer containing 40 mM Tris, pH 7.5, 10 mM MgCl2, andmM spermidine. The final volume was 25 ml. Reactions
were incubated at 37°C. Then 5 ml of reaction solution was
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277HIV-1 REPLICATION INHIBITION BY HAIRPIN RIBOZYME GENE THERAPYremoved and mixed with 5 ml of termination solution (10 M
urea, 0.25% xylene cyanol, 0.25% bromphenol blue) at 0, 30,
60, 90, and 120 min. The reaction products were resolved
on a denaturing 20% polyacrylamide gel containing 7 M
urea. The degree of substrate cleavage was determined by
densitometry on a Molecular Dynamics Phosphorimager
(Molecular Dynamics). The kinetic properties of the ri-
bozymes were further characterized, as described (Hampel
and Tritz, 1989).
Generation of rAAV vectors and CCR5 ribozyme-
expressing PM1 cells
To construct rAAV vectors, the retroviral vector, pLNL-6
(Yu et al., 1993), was digested with SacII, which left the 59
LTR intact and truncated the 39 LTR. This fragment was
cloned into pSUB201 (Samulski et al., 1987), a kind gift
from R. J. Samulski, using XbaI linkers. Since the trunca-
tion of the 39 LTR resulted in removal of the retroviral
polyadenylation signal, a SV40 poly A site was added at
the XhoI site. A tRNA ribozyme expression cassette was
removed from plasmid JT-HR (Yu et al., 1993) by EcoRI,
phI digestion and blunt end-cloned into the HindIII site
f the pSUB201-derived plasmid, resulting in the pAMFT
lasmid. The DNA fragments encoding individual CCR5
ibozymes were generated from oligonucleotides and
loned into the BamHI, MluI-digested pAMFT (Fig. 1).
AAV was generated from pAMFT as previously de-
cribed (Mamounas et al., 1995). PM1 cells were infected
ith the rAAV at an m.o.i. of 0.1. Transduced cultures
ere selected and expanded in RPMI medium contain-
ng 1000 mg/ml G418 for at least 3 weeks to insure that
stable integration of rAAV had occurred.
Fluorescence-activated cell sorter (FACS) analysis
Cell surface CCR5 was determined by FACS analysis
using PE-conjugated anti-human CCR5 monoclonal an-
tibody 2D7/CCR5 (PharMingen). The preparation and an-
tibody-staining of cells were carried out according to the
manufacture. The FACS analysis was performed on a
FACScan flow cytometer. Each cell population was gated
versus the corresponding isotype control.
Cell fusion assays
Membrane fusion between HIV-1 env-expressing cells
and CD4/coreceptor-expressing cells was measured by
a reporter gene assay as described by Broder and
Berger (Broder and Berger, 1995). Briefly, PM1 cells were
coinfected with vaccinia recombinant vCB-3, which con-
tains a human CD4 expression cassette, and vCB21R-
lacZ, which contains the lacZ gene under a T7 promoter,
to overexpress CD4 on the cell surface as well as to
bring the lacZ gene into the cytoplasm. Meanwhile, HeLa
cells were infected with vTF7-3 and either vCB43 or
vSC60 to express T7 RNA polymerase in the cytoplasm
and HIV-1 env on the cell surface. vTFT7-3 contains a T7RNA polymerase expression cassette. vCB43 contains
an HIV-1 Ba-L env expression cassette and vSC60 con-
tains a HIV-1 IIIB env expression cassette. The PM1 cells
(105) and HeLa cells (105) were mixed and incubated at
37°C for 2 h. The cells were then lysed and aliquots of
the lysate were assayed for b-galactosidase activity with
the substrate chlorophenol red b-D-galactopyranoside.
Viral challenge assay
PM1 cells and the stably transduced PM1 cells were
infected with HIV-1 IIIB or Ba-L at an m.o.i. of 0.02 for a
period of 2 h. The cells were washed and replated in
RPMI with 10% fetal bovine serum. The cell cultures were
refed with one-half volume of fresh medium every 2 to 3
days and were monitored for HIV production by p24
ELISA (Organon Technica).
Detection of CCR5 mRNA
mRNA was isolated from cells and purified using
oligo-dT cellulose. One microgram of mRNA was sepa-
rated on a 1% agarose–formaldehyde gel and transferred
to a nylon membrane. It was then hybridized with CCR5-
specific probes generated by random primers using
CCR5 cDNA as the template. Messenger RNA was nor-
malized using b-actin mRNA as a standard. b-Actin
RNA was detected by hybridizing with a b-actin probe
nd quantified using a Molecular Dynamics Phosphorim-
ger. CCR5 and G3PDH (internal control) mRNA from
M1 cells was also analyzed by RT QC-PCR, in which
RNA was reverse transcribed and quantified by PCR
mplification against competitive DNA mimic fragments
Clontech).
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